CAR-T cell immunotherapy

Phase 1Cell therapy

FFuda Cancer Hospital, Guangzhou

CAR-T cell immunotherapy is one of 136 biologic programs targeting Glioma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

135

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Malignant GliomaActive, not recruiting

Prostate CancerActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

GliomaPhase 1/Phase 2

Active, not recruiting

Malignant GliomaPhase 1/Phase 2

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Renal Cell CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Triptorelin Pamoate

Ipsen

Preclinical

2 6

CAR-T cell immunotherapy

FFuda Cancer Hospital, Guangzhou

Phase 1

1 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

—8

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—9

Osmitrol

BB. Braun Medical Inc.

Preclinical

—10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Renal Cell Carcinoma

NCT04969354

Q4 2026

Phase 1Recruiting

Prostate Cancer

NCT05354375

Clinical

Trials by Indication[1]

Immunotherapy2 trials

CAR-T Cell Immunotherapy for HCC Targeting GPC3

Withdrawn·FFuda Cancer Hospital, Guangzhou·Phase 1/2·NCT02723942

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Unknown status·SShenzhen BinDeBio Ltd.·Phase 1/2·NCT03638206·73 enrolled

Advanced1 trial

GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1·NCT04121273·20 enrolled

T Cells1 trial

A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer

Unknown status·FFirst Affiliated Hospital of Chengdu Medical College·Phase 1/2·NCT03013712·60 enrolled

Renal Cell Carcinoma1 trial

Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma

Recruiting·TThe Affiliated Hospital of Xuzhou Medical University·Phase 1·NCT04969354·20 enrolled

Glioma1 trial

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

Withdrawn·FFuda Cancer Hospital, Guangzhou·Phase 1/2·NCT03252171

2 more indications

Malignant Glioma1 trial

CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients

Withdrawn·FFuda Cancer Hospital, Guangzhou·Phase 1/2·NCT02575261

Prostate Cancer1 trial

Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer

Recruiting·TThe Affiliated Hospital of Xuzhou Medical University·Phase 1·NCT05354375·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for CAR-T cell immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAR-T cell immunotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAR-T cell immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fuda Cancer Hospital, Guangzhou company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: FFuda Cancer Hospital, Guangzhou

CAR-T cell immunotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Immunotherapy2 trials

Advanced1 trial

T Cells1 trial

Renal Cell Carcinoma1 trial

Glioma1 trial

Malignant Glioma1 trial

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News